Real study: Re-treatment evaluated on visual acuity for Lucentis

To assess the value of a monthly injection of LucentisProspective, single-center, non-controlled trial including naïve AMD patients with neovascularization. An assessment of VA and a spectral domain optical coherence tomography (SD-OCT) were performed at baseline and every month. Monthly injections of LucentisFifteen out of the 21 patients included were anatomically good responders. A mean gain of +14Le (9) was obtained up to the point at which there was no exudation. There was no additional gain from this point until 3 consecutive stable VA results were obtained. During the PRN phase, an additional mean gain of +3.2Le (7.7) was obtained.This initial VA-guided regimen with ranibizumab might prevent the slight decrease in VA observed during the first year of PRN studies.